rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cytek Biosciences, Inc.

CTKB · Nasdaq

Health CareLife-science toolsIn trend

CTKB stood above a rising 150-day average in 21 of the last 52 weekly readings, including each of the last 4 weeks. It is 14.4% above that average now. Life Science Tools & Research Services: 54% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
4 in a row
Industry in uptrend
54% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
1
Institutions holding
147 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 21 of 52 weeks.

20 Apr – 19 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$94KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 0, Senate 0, executive 1; 1 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k15 May 2026filed 1 Jul 2026

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders147-2 on the quarter
New · exited31 · 33
Reported value$354.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.reduced · filed 7 Aug 20269,578,643$42.4M-7,428,626−43.7%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20269,338,010$41.4M+3,046,212+48.4%
Boston Partnersadded · filed 4 Aug 20267,660,943$33.9M+1,858,170+32.0%
HHLR ADVISORS, LTD.unchanged · filed 14 Aug 20266,657,030$29.5M00.0%
Topline Capital Management, LLCreduced · filed 14 Aug 20266,283,450$27.8M-781,031−11.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20264,939,597$21.9M+176,693+3.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20263,059,573$13.6M+225,618+8.0%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 20262,616,257$11.6M-47,072−1.8%
STATE STREET CORPreduced · filed 7 Aug 20262,566,121$11.4M-1,557,627−37.8%
GOLDMAN SACHS GROUP INCreduced · filed 14 Aug 20262,167,515$9.6M-177,220−7.6%
31 Mar 2023 – 30 Jun 2026
80113146Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Glenn P. Muir Company insiderDirector · last 18 Aug 20260 · 0
Michael Holder Company insiderDirector · last 18 Aug 20260 · 0
Ming Yan Company insiderCHIEF TECHNOLOGY OFFICER · last 18 Aug 20260 · 30
Richard Chin Company insiderDirector · last 18 Aug 20260 · 0
Wenbin Jiang Company insiderPRESIDENT AND CEO · last 18 Aug 20260 · 22
William D. McCombe Company insiderChief Financial Officer · last 18 Aug 20261 · 0
Ilan Feuchtwang Company insiderChief Legal Officer, Secretary · last 10 Aug 20260 · 0
Deborah J. Neff Company insiderDirector · last 10 Jun 20260 · 0
Jack Ball Company insiderDirector · last 10 Jun 20261 · 1
Vera Imper Company insiderDirector · last 10 Jun 20260 · 0
Philippe Busque Company insiderSVP, GLOBAL SALES AND SERVICES · last 18 May 20260 · 0
Valerie Barnett Company insiderCHIEF LEGAL OFFICER · last 18 May 20261 · 0

Same industry

OABI OmniAbLeading+67%
TXG 10x GenomicsLeading+59%
AVTR AvantorLeading+45%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+35%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202551.8%
Operating profit marginFY 2025 · to 31 Dec 2025-20.0%
Free cash flow marginFY 2025 · to 31 Dec 2025-4.4%
Return on capital employedFY 2025 · to 31 Dec 2025-10.5%
Research spendFY 2025 · to 31 Dec 202518.1%
Share count trendFY 2025 · to 17 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$90.9M
Free cash flowFY 2025 · to 31 Dec 2025−$8.8M

Analyst forecasts

No analyst forecasts yet.